Recently, corticotropin-releasing hormone (CRH) has been highlighted as a potential CSF biomarker for Lewy body disease, being decreased in dementia with Lewy bodies compared with Alzheimer’s disease patients and healthy individuals.12 CRH is a secretagogue mainly expressed in the paraventricular nucleus (PVN) in the hypothalamus, activating the hypothalamus–pituitary–adrenal (HPA) axis and promoting the release of cortisol by the adrenal cortex, therefore, responsible for stress and inflammatory response.13 Brain and CSF studies have implicated CRH in several neurodegenerative diseases. This evidence concerns the gene CRH and early-onset autosomal dominant Alzheimer disease.